What Concept Medical does

Concept Medical Research Private Limited is a privately held medical device company founded in 2008 that develops sirolimus-based drug delivery platforms for vascular interventions. The company serves interventional cardiologists and vascular specialists globally, operating through direct enterprise field sales in over 80 countries. Primary therapeutic indications are coronary artery disease (CAD), peripheral artery disease (PAD), arteriovenous fistula/graft maintenance for hemodialysis patients, and vasculogenic erectile dysfunction. The corporate footprint spans Surat, India (manufacturing and registered office), Tampa, Florida (US headquarters), and Hoevelaken, the Netherlands (European headquarters), with Fort Lee, New Jersey serving as an administrative office.

The product portfolio is built on three proprietary technology platforms: Nanolute Technology (submicron sirolimus encapsulated in phospholipid for improved lipophilicity and tissue retention), Nanoactive Technology (pro-healing submicron particles for faster endothelialization and lower late-lumen loss), and Envisolution Technology (abluminal-only sirolimus coating with biodegradable polymer used in the Abluminus stent line). The MagicTouch family of sirolimus-coated balloons includes four indication-specific variants — SCB (coronary), PTA (peripheral), AVF (dialysis access), and ED (erectile dysfunction). MagicTouch SCB received the world's first CE Mark for a commercially approved sirolimus-coated balloon in coronary use in 2016. The Abluminus DES+ (biodegradable polymer) and Abluminus NP DES (polymer-free) extend the franchise into drug-eluting stents, with the latter receiving CE Mark approval in 2026. The company holds five FDA Investigational Device Exemption approvals for US pivotal clinical trials.

Concept Medical generates revenue through hardware sales of medical devices to hospitals and healthcare institutions. Pricing is quote-based and not publicly disclosed, varying by procedure type, volume, and geography. The company claims one of the largest sirolimus-coated balloon clinical programs globally, with over 10,000 patients studied across trials including SIRONA (88.2% vs 80.2% freedom from clinically-driven TLR at 3 years versus paclitaxel-coated balloon, HR 0.60, p=0.03), SirPAD (1,252 patients), and the ongoing STARS DAPT trial. No revenue figures, venture capital investors, or institutional ownership are disclosed; the company appears to be founder-controlled with a single disclosed $60M funding round in 2018.

Name

Concept Medical

Legal name

Concept Medical Research Private Limited

Website

https://conceptmedical.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

51–100 employees

Short description

Concept Medical is a private medical device company developing sirolimus-based drug-coated balloons (MagicTouch) and drug-eluting stents (Abluminus) for coronary, peripheral, dialysis-access, and erectile dysfunction interventions, sold directly to hospitals in over 80 countries.

Ownership category

akta.pro rank

Product category

Vascular Intervention Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Coronary Stents & Drug-Eluting Technologies (HLAHAFAA)

akta.pro secondary industry

Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE)

Keywords

• Drug-coated balloons
• Drug-eluting stents
• Vascular intervention devices
• Sirolimus delivery platforms
• Endovascular medical devices

Headquarters

HQ city

Tampa

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Concept Medical generates revenue through the sale of advanced endovascular devices including Drug-Coated Balloons (DCB) and Drug-Eluting Stents (DES) for coronary and peripheral interventions. The company operates globally in over 80 countries through direct sales to healthcare institutions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Concept Medical develops and manufactures advanced endovascular medical devices based on proprietary sirolimus drug-delivery platforms. The company produces Drug-Coated Balloons (MagicTouch SCB, PTA, AVF, ED) and Drug-Eluting Stents (Abluminus DES+, Abluminus NP DES) used by interventional cardiologists and vascular surgeons for the treatment of coronary artery disease, peripheral artery disease, dialysis access maintenance, and vasculogenic erectile dysfunction. Revenue is generated primarily through direct sales of these physical medical devices to hospitals and healthcare institutions in over 80 countries.

Product overview

Concept Medical is a medical device company specializing in sirolimus-based drug delivery platforms for cardiovascular and peripheral vascular interventions. The product portfolio centers on two main technology platforms: Drug-Coated Balloons (DCB) and Drug-Eluting Stents (DES). The MagicTouch family of sirolimus-coated balloons includes four indications: MagicTouch SCB for coronary artery disease, MagicTouch PTA for peripheral arterial disease, MagicTouch AVF for dialysis fistulas/grafts, and MagicTouch ED for erectile dysfunction. The Abluminus DES+ offers an abluminal sirolimus coating with biodegradable polymer for high-risk patients, while Abluminus NP DES provides a polymer-free sirolimus stent option. Supporting accessories include the Midas PTA Dilatation Catheter and Transport AC. All products leverage proprietary technologies (Nanolute, Nanoactive, Envisolution) for efficient sirolimus delivery without permanent implantation in the case of DCBs.

Differentiator

Problem solved

Functional benefit

Brands

• MagicTouch: Proprietary Sirolimus-Coated Balloon platform for vascular interventions including SCB (coronary), PTA (peripheral), AVF (dialysis fistulas), and ED (erectile dysfunction) applications
• Abluminus DES+
• Abluminus NP
• Nanolute Technology
• Nanoactive Technology
• Envisolution Technology

Products and services

• MagicTouch SCB Sirolimus-Coated Balloon for the treatment of coronary artery disease. The world's first commercially approved SCB for coronary use (CE Mark in 2016). Delivers sirolimus directly to vessel walls during angioplasty without leaving any permanent implant.
• MagicTouch PTA Sirolimus-Coated PTA (Percutaneous Transluminal Angioplasty) Balloon Catheter for the treatment of peripheral arterial disease. Uses Nanolute technology for precise sirolimus delivery and uniform coating with no implant left behind.
• MagicTouch AVF Sirolimus-Coated Balloon for arteriovenous fistula/graft (AVF/AVG) maintenance in dialysis patients. Designed to maintain patency of dialysis-related fistulas and grafts without permanent implantation.
• MagicTouch ED Sirolimus-Coated Balloon for the treatment of vasculogenic erectile dysfunction. Offers a drug-coated balloon approach for this indication using the proprietary Nanolute sirolimus delivery platform.
• ABLUMINUS DES+ Drug-eluting stent with abluminal sirolimus coating and Fusion coating technology combined with biodegradable polymer. Features abluminally-only coating for targeted healing, designed for diabetic and high-risk patients. Coating on both stent and exposed balloon parts facilitates homogenous drug delivery addressing diffused proliferative disease and focal restenosis.
• ABLUMINUS NP DES Polymer-free sirolimus-eluting stent designed to minimize long-term inflammation and foreign body response while supporting faster healing. Uses Nanoactive technology for submicron drug delivery and enhanced tissue retention.
• Midas PTA Dilatation Catheter PTA dilatation catheter accessory for use in peripheral interventions. Part of Concept Medical's accessory portfolio supporting their drug-coated balloon and drug-eluting stent product lines.
• Transport AC Accessory product for catheter-based procedures. Part of Concept Medical's accessory portfolio supporting their vascular intervention product lines.

Quantifiable outcome

• 88.2% vs 80.2% freedom from clinically-driven target lesion revascularization at 3 years (HR 0.60, p=0.03)
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Clinical Trial Investigator Sites (Multiple International Centers)coreStrategic or Co-development Partner · 22 January 2026Multi-center international clinical trial network spanning Switzerland, UK, Italy, The Netherlands, Austria, Germany, Singapore, Taiwan, Thailand, South Korea, USA, Brazil, Japan, Spain, and Poland for SIRONA, SirPAD, Transform II, TITAN, and other pivotal trials.
• University Hospital of ZurichcoreStrategic or Co-development PartnerPrincipal investigator site for STARS DAPT randomized clinical trial evaluating Abluminus NP polymer-free DES for STEMI patients. First patient enrollment initiated by Professor Barbara Stähli's team.
• Geneva University HospitalscoreStrategic or Co-development PartnerLed by Principal Investigator PD Dr. Juan F. Iglesias for STARS DAPT trial evaluating short DAPT duration with Abluminus NP polymer-free DES in STEMI patients across multiple international centers.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Medtronic: Medtronic's IN.PACT Admiral DCB and Resolute DES family compete head-to-head with Concept Medical's MagicTouch and Abluminus platforms across coronary and peripheral vascular indications.
• Terumo: Terumo's Kanshas drug-coated balloon and broader interventional portfolio compete with MagicTouch in peripheral and coronary vascular interventions across global markets.
• Shockwave Medical (J&J): Shockwave's intravascular lithotripsy (IVL) platform competes with DCB approaches for peripheral and coronary vessel preparation, addressing overlapping clinical decision points in vascular intervention.
• Becton Dickinson (BD): BD's Lutonix drug-coated balloon (acquired via Bard) competes directly with MagicTouch PTA in peripheral arterial disease and with broader DES portfolios via its peripheral vascular franchise.
• Boston Scientific: Boston Scientific markets the Agent drug-coated balloon and Promus DES portfolio — overlapping with Concept Medical across both DCB and DES categories in coronary and peripheral vascular interventions.

Direct peers

• Biotronik: Biotronik markets the Orsiro sirolimus-eluting stent and Pantera Lux DCB — overlapping technology platforms (sirolimus drug-eluting) and overlapping customer base in interventional cardiology.
• Cordis (Cardinal Health): Cordis's SELUTION SLR sirolimus-coated balloon is the closest direct competitor to MagicTouch — same active pharmaceutical, same DCB mechanism, similar coronary and peripheral indication strategy.
• B. Braun: B. Braun's SeQuent Please is one of the most established sirolimus-coated balloons in Europe, directly competing with Concept Medical's MagicTouch SCB in the same cath-lab use case with the same active pharmaceutical.

Emerging players

• SurModics: SurModics develops drug-coated balloon coating technology used by partners to commercialize DCBs — directly adjacent to Concept Medical's Nanolute platform in the DCB value chain.
• iVascular: iVascular markets the Essential sirolimus-coated balloon and other peripheral and coronary devices, competing with Concept Medical in similar cath-lab indications especially in European and Latin American markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/conceptmedicals
• YouTubeyoutube.com/@conceptmedicalinc
• Facebookfacebook.com/conceptmedicalinc
• LinkedInlinkedin.com/company/conceptmedicalinc
• Instagraminstagram.com/conceptmedicalinc

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Concept Medical